Key result
An IFN-gamma-expressing recombinant coxsackievirus vector completely protects animals against subsequent lethal CVB3 infections by activating the immune system in a strong and long-lasting manner.
Why the study?
Does an IFN-gamma-expressing recombinant coxsackievirus vector prevent CVB3-induced myocarditis in animal models?
Does an IFN-gamma-expressing recombinant coxsackievirus vector prevent CVB3-induced myocarditis in animal models?
Recombinant coxsackievirus vectors expressing IFN-gamma represent a promising preclinical vaccine strategy for preventing CVB3-induced myocarditis.
Answers are grounded in this paper and cite their sources.
Supports preclinical IFN-gamma vector vaccines for CVB3; leaves open human translation and efficacy.
Coxsackievirus B3 (CVB3), a member of the Picornaviridae family, is considered to be one of the most important infectious agents to cause virus-induced myocarditis. Despite improvements in studying virus pathology, structure and molecular biology, as well as the diagnosis of this disease, there is still no virus-specific drug or vaccine in clinical use. During the last 20 years many investigations have been performed to develop classic and modern immunization techniques against CVB3-induced heart disease. One promising approach among others includes the insertion of coding sequences of cytokines into the viral genome. The application of an IFN-gamma-expressing recombinant coxsackievirus vector is especially efficient against CVB3-induced myocarditis. Beside direct IFN-gamma-mediated antiviral effects, the local and simultaneous expression of IFN-gamma by the virus itself activates the immune system in a strong and long-lasting manner, which protects animals completely against subsequent lethal infections independently of the age of the immunized individual and the route of vaccine administration.
No takes yet. Share an insight, caveat, or question.
Henke et al. (2008) conducted a review in CVB3-induced myocarditis. IFN-gamma-expressing recombinant coxsackievirus vector was evaluated on Protection against subsequent lethal infections. An IFN-gamma-expressing recombinant coxsackievirus vector completely protects animals against subsequent lethal CVB3 infections by activating the immune system in a strong and long-lasting manner.
Synapse has enriched 10 related papers. Consider them for comparative context: